PL412704A1 - Pochodne fosfonooksychinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowanie - Google Patents

Pochodne fosfonooksychinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowanie

Info

Publication number
PL412704A1
PL412704A1 PL412704A PL41270403A PL412704A1 PL 412704 A1 PL412704 A1 PL 412704A1 PL 412704 A PL412704 A PL 412704A PL 41270403 A PL41270403 A PL 41270403A PL 412704 A1 PL412704 A1 PL 412704A1
Authority
PL
Poland
Prior art keywords
compositions
derivatives
phosphonooxyquinazoline
pharmaceutical application
therapy
Prior art date
Application number
PL412704A
Other languages
English (en)
Other versions
PL223998B1 (pl
Inventor
Heron Nicola Murdoch
Frederic Henri Jung
Pasquet Georges Rene
Andrew Austen Mortlock
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL412704A1 publication Critical patent/PL412704A1/pl
Publication of PL223998B1 publication Critical patent/PL223998B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Przedmiotem wynalazku są pochodne chinazoliny o wzorze (I), w którym A oznacza 5 - członową grupę heteroarylową, zawierającą atom azotu i jeden lub dwa dalsze atomy azotu; zawierające je kompozycje, sposoby ich wytwarzania oraz ich zastosowanie w terapii.
PL412704A 2002-12-24 2003-12-22 N-(3-Fluorofenylo)-2-{3-[(7-{3-[etylo(2-hydroksyetylo)amino]propoksy}chinazolin-4-ylo)amino]-1H-pirazol-5-ilo} acetamid oraz jego kompozycja farmaceutyczna PL223998B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02293238 2002-12-24
EP03291315 2003-06-02

Publications (2)

Publication Number Publication Date
PL412704A1 true PL412704A1 (pl) 2015-10-12
PL223998B1 PL223998B1 (pl) 2016-11-30

Family

ID=32683824

Family Applications (2)

Application Number Title Priority Date Filing Date
PL377680A PL221490B1 (pl) 2002-12-24 2003-12-22 Pochodne fosfonooksychinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
PL412704A PL223998B1 (pl) 2002-12-24 2003-12-22 N-(3-Fluorofenylo)-2-{3-[(7-{3-[etylo(2-hydroksyetylo)amino]propoksy}chinazolin-4-ylo)amino]-1H-pirazol-5-ilo} acetamid oraz jego kompozycja farmaceutyczna

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL377680A PL221490B1 (pl) 2002-12-24 2003-12-22 Pochodne fosfonooksychinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania

Country Status (30)

Country Link
US (4) US7528121B2 (pl)
EP (2) EP1578755B1 (pl)
JP (3) JP4422102B2 (pl)
KR (1) KR101010299B1 (pl)
AR (2) AR042668A1 (pl)
AT (2) ATE370958T1 (pl)
AU (1) AU2003290313B2 (pl)
BR (1) BRPI0317717B8 (pl)
CA (1) CA2511613C (pl)
CL (1) CL2003002731A1 (pl)
CY (2) CY1107775T1 (pl)
DE (2) DE60328735D1 (pl)
DK (2) DK1847539T3 (pl)
ES (2) ES2290529T3 (pl)
HK (2) HK1080481A1 (pl)
IL (2) IL169112A (pl)
IS (2) IS2504B (pl)
MX (1) MXPA05006918A (pl)
MY (2) MY147761A (pl)
NO (2) NO335193B1 (pl)
NZ (1) NZ540698A (pl)
PL (2) PL221490B1 (pl)
PT (2) PT1847539E (pl)
RU (3) RU2350611C1 (pl)
SA (1) SA04240504B1 (pl)
SI (2) SI1847539T1 (pl)
TW (2) TWI336327B (pl)
UA (1) UA83814C2 (pl)
UY (1) UY28149A1 (pl)
WO (1) WO2004058781A1 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1463506T3 (da) * 2001-12-24 2010-01-11 Astrazeneca Ab Substituerede quinazolin-derivater som inhibitorer af aurora-kinaser
JP2006516138A (ja) * 2002-12-24 2006-06-22 アストラゼネカ アクチボラグ キナゾリン化合物
ES2290529T3 (es) * 2002-12-24 2008-02-16 Astrazeneca Ab Derivados de fosfonooxiquinazolina y su uso farmaceutico.
CL2004000797A1 (es) * 2003-04-16 2005-05-27 Astrazeneca Ab Compuestos derivados de quinazolina, inhibidores de aurora quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para preparar un medicamento para tratar cancer colorrectal, de mama, de pulmon, de prostata, de vejiga, renal o panc
AU2004247626B8 (en) * 2003-05-15 2011-05-19 Arqule, Inc. Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
ATE401080T1 (de) * 2003-06-02 2008-08-15 Astrazeneca Ab (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
WO2006040520A1 (en) 2004-10-12 2006-04-20 Astrazeneca Ab Quinazoline derivatives
JP2008515961A (ja) * 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ 癌に対する使用のためのキナゾリン誘導体
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8178672B2 (en) * 2004-10-19 2012-05-15 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US7501430B2 (en) * 2006-04-17 2009-03-10 Arqule, Inc. RAF inhibitors and their uses
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
MX2009003793A (es) 2006-10-09 2009-12-14 Takeda Pharmaceutical Inhibidores de cinasa.
WO2009111028A1 (en) * 2008-03-04 2009-09-11 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
CA2722220C (en) 2008-04-30 2016-06-07 National Health Research Institutes Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
JP2011526912A (ja) * 2008-07-03 2011-10-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング プロテインキナーゼ阻害剤としてのナフチリジノン
US20100183600A1 (en) * 2008-12-05 2010-07-22 Arqule, Inc. RAF Inhibitors and Their Uses
CA2746652C (en) 2008-12-11 2018-03-06 Axcentua Pharmaceuticals Ab Crystalline forms of genistein
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
CA2747326C (en) 2008-12-22 2017-05-16 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
BR112013022307A2 (pt) 2011-03-04 2020-09-24 Glaxosmithkline Intellectual Property (No. 2) Limited aminoquinolinas como inibidores de quinase
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
CA2900652C (en) 2013-02-15 2021-05-04 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
JP2016510000A (ja) 2013-02-20 2016-04-04 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物およびその使用
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2654100T3 (es) * 2013-02-21 2018-02-12 Glaxosmithkline Intellectual Property Development Limited Quinazolinas como inhibidores de quinasa
CN105555315B (zh) * 2013-09-16 2019-05-07 阿斯利康(瑞典)有限公司 治疗性聚合物纳米颗粒及其制备和使用方法
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2014342042B2 (en) 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015085289A1 (en) 2013-12-06 2015-06-11 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
EP3509422A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
EP3678668B1 (en) 2017-09-08 2024-01-10 The Board of Trustees of the Leland Stanford Junior University Enpp1 inhibitors and their use for the treatment of cancer
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN112939948B (zh) * 2019-12-11 2022-05-17 苏州美诺医药科技有限公司 新型含喹唑啉类化合物及其中间体与应用
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2022192139A1 (en) 2021-03-10 2022-09-15 Astrazeneca Ab Aurora kinase b inhibitors for use for treating cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU2737295A (en) 1994-06-09 1996-01-04 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (pl) 1994-11-12 1997-12-01 Zeneca Ltd
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
JP3944241B2 (ja) 1995-12-18 2007-07-11 スージェン・インコーポレーテッド Ａｕｒ―１および／またはａｕｒ―２関連疾患の診断および処置
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
DK0885198T3 (da) 1996-03-05 2002-03-25 Astrazeneca Ab 4-Anilinoquinazolinderivater
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ES2241324T3 (es) 1998-10-08 2005-10-16 Astrazeneca Ab Derivados de quinazolina.
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CN1391562A (zh) 1999-09-21 2003-01-15 阿斯特拉曾尼卡有限公司 用作药物的喹唑啉衍生物
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
CA2406979A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
MXPA02011974A (es) 2000-06-28 2004-09-06 Astrazeneca Ab Derivados de quinazolina sustituidos y su uso como inhibidores.
AU2001266233B2 (en) 2000-07-07 2006-06-29 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
RU2003103603A (ru) 2000-07-07 2004-08-20 Энджиоджен Фармасьютикалз Лимитед (Gb) Производные колхинола в качестве ингибиторов ангиогенеза
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2003000188A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
DK1463506T3 (da) 2001-12-24 2010-01-11 Astrazeneca Ab Substituerede quinazolin-derivater som inhibitorer af aurora-kinaser
JP2006516138A (ja) * 2002-12-24 2006-06-22 アストラゼネカ アクチボラグ キナゾリン化合物
ES2290529T3 (es) * 2002-12-24 2008-02-16 Astrazeneca Ab Derivados de fosfonooxiquinazolina y su uso farmaceutico.
CL2004000797A1 (es) * 2003-04-16 2005-05-27 Astrazeneca Ab Compuestos derivados de quinazolina, inhibidores de aurora quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para preparar un medicamento para tratar cancer colorrectal, de mama, de pulmon, de prostata, de vejiga, renal o panc

Also Published As

Publication number Publication date
AU2003290313B2 (en) 2007-05-10
RU2357971C2 (ru) 2009-06-10
SA04240504B1 (ar) 2008-04-01
HK1080481A1 (en) 2006-04-28
TW201102369A (en) 2011-01-16
IS2884B (is) 2014-06-15
RU2350611C1 (ru) 2009-03-27
EP1578755B1 (en) 2007-08-22
KR20050088333A (ko) 2005-09-05
JP2009046514A (ja) 2009-03-05
EP1847539B1 (en) 2009-08-05
KR101010299B1 (ko) 2011-01-25
EP1847539A1 (en) 2007-10-24
IS8714A (is) 2008-02-13
US20100069412A1 (en) 2010-03-18
IL169112A (en) 2010-12-30
US9567358B2 (en) 2017-02-14
JP2006512418A (ja) 2006-04-13
PL377680A1 (pl) 2006-02-06
JP4503090B2 (ja) 2010-07-14
BRPI0317717B1 (pt) 2017-12-19
DK1847539T3 (da) 2009-11-09
NZ540698A (en) 2008-05-30
JP4906608B2 (ja) 2012-03-28
UA83814C2 (ru) 2008-08-26
TW200510342A (en) 2005-03-16
PL221490B1 (pl) 2016-04-29
DE60328735D1 (de) 2009-09-17
NO335193B1 (no) 2014-10-20
EP1578755A1 (en) 2005-09-28
PT1578755E (pt) 2007-10-19
MY147761A (en) 2013-01-31
AR042668A1 (es) 2005-06-29
AR057753A2 (es) 2007-12-19
BR0317717A (pt) 2005-11-22
BRPI0317717B8 (pt) 2021-05-25
ATE370958T1 (de) 2007-09-15
SI1847539T1 (sl) 2010-01-29
DK1578755T3 (da) 2007-11-12
IS2504B (is) 2009-04-15
AU2003290313A1 (en) 2004-07-22
SI1578755T1 (sl) 2007-12-31
US20140162984A1 (en) 2014-06-12
TWI336327B (en) 2011-01-21
IL185176A0 (en) 2007-12-03
US20060116357A1 (en) 2006-06-01
SA04240504A (ar) 2005-12-03
IS7948A (is) 2005-07-20
TWI393710B (zh) 2013-04-21
US8268841B2 (en) 2012-09-18
JP4422102B2 (ja) 2010-02-24
ES2290529T3 (es) 2008-02-16
PL223998B1 (pl) 2016-11-30
DE60315892D1 (de) 2007-10-04
ATE438644T1 (de) 2009-08-15
WO2004058781A1 (en) 2004-07-15
CL2003002731A1 (es) 2005-01-07
UY28149A1 (es) 2004-07-30
DE60315892T2 (de) 2008-08-14
US7528121B2 (en) 2009-05-05
MXPA05006918A (es) 2005-08-18
IL185176A (en) 2011-10-31
CY1109479T1 (el) 2014-08-13
IL169112A0 (en) 2009-02-11
RU2007121850A (ru) 2008-12-20
CA2511613C (en) 2012-10-02
US20150307534A1 (en) 2015-10-29
RU2005123485A (ru) 2006-03-10
PT1847539E (pt) 2009-10-06
NO20131444L (no) 2005-08-03
JP2007326862A (ja) 2007-12-20
CY1107775T1 (el) 2013-06-19
NO335446B1 (no) 2014-12-15
MY136174A (en) 2008-08-29
CA2511613A1 (en) 2004-07-15
ES2329623T3 (es) 2009-11-27
NO20052855D0 (no) 2005-06-13
NO20052855L (no) 2005-08-03
HK1111417A1 (en) 2008-08-08
US9018191B2 (en) 2015-04-28

Similar Documents

Publication Publication Date Title
PL412704A1 (pl) Pochodne fosfonooksychinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowanie
DE60324461D1 (de) Therapeutische quinazolin-derivate
MXPA05006920A (es) Compuestos de quinazolina.
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
BR0308787A (pt) Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
SE0101387D0 (sv) Novel compounds
NO20071074L (no) Substituerte cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
IS7552A (is) Bensótengdar heteróarýl amíð afleiður af þíenópýridíni, gagnlegar sem meðferðarmiðlar, lyfjasamsetningar sem innihalda þær og aðferðir við notkun þeirra
SE0202133D0 (sv) Novel compounds
HUP0300743A2 (hu) Heteroarilszármazékok és alkalmazásuk gyógyszerként
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
GB0114286D0 (en) Nucleoside Derivatives
ATE433981T1 (de) Heterocyclische verbindungen
MXPA03006363A (es) Derivados de urea como antagonistas de integrinas alfa-4.
WO2003091259A8 (en) Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
SE0101932D0 (sv) Pharmaceutical combinations
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
DK1483251T3 (da) C3-cyano-epothilon-derivater
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200628153A (en) Novel compounds
ATE485822T1 (de) Phenylaminopyridine und phenylaminopyrazine
HUP0201475A2 (hu) Heteroarilamidin-, metilamidin- és guanidinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
MY134026A (en) ?-carboline derivatives and its pharmaceutical use against depression and anxiety